Literature DB >> 618708

Binding of quinidine to plasma proteins in normal subjects and in patients with hyperlipoproteinemias.

R E Kates, T D Sokoloski, T J Comstock.   

Abstract

Quinidine in the plasma binds to various lipoproteins as well as to albumin. With the use of computer simulations the effect of varying the serum level of each of the lipoproteins as well as albumin was examined. The results suggested that the overall binding of quinidine is relatively insensitive to changes in any one serum protein provided the others are present in normal concentrations. Evaluation of the degree of protein binding of quinidine in plasma from normal subjects and patients with types IV and IIa hyperlipoproteinemias supported the computer predictions. The degree of protein binding in plasma from normal subjects and patients with types IV and IIA hyperlipoproteinemias were 71.2% +/- 11.4%, 75.9% +/- 8.7%, and 69.9% +/- 15.0%, respectively. The quinidine binding in plasma of patients with hyperlipoproteinemias did not differ statistically from that in the normal subjects.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618708     DOI: 10.1002/cpt197823130

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

Review 2.  Methodological aspects of the evaluation of the binding of drugs to plasma and tissue proteins.

Authors:  J P Tillement; E Albengres; S Urien
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

Review 3.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

4.  Altered quinidine disposition in a patient with chronic active hepatitis.

Authors:  J R Powell; R Okada; K A Conrad; T W Guentert; S Riegelman
Journal:  Postgrad Med J       Date:  1982-02       Impact factor: 2.401

Review 5.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.

Authors:  E Pike; P Kierulf; B Skuterud; J E Bredesen; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

7.  Effects of Na+ channel blockers on the restitution of refractory period, conduction time, and excitation wavelength in perfused guinea-pig heart.

Authors:  Oleg E Osadchii
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.